163 related articles for article (PubMed ID: 27067491)
21. Nilotinib in the treatment of chronic myeloid leukemia.
Sacha T; Saglio G
Future Oncol; 2019 Mar; 15(9):953-965. PubMed ID: 30547682
[TBL] [Abstract][Full Text] [Related]
22. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
[TBL] [Abstract][Full Text] [Related]
23. Targeted drugs in chronic myeloid leukemia.
Gora-Tybor J; Robak T
Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651
[TBL] [Abstract][Full Text] [Related]
24. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
25. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
DeAngelo DJ; Attar EC
Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
[TBL] [Abstract][Full Text] [Related]
26. Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.
Woywod C; Gruber FX; Engh RA; Flå T
PLoS One; 2017; 12(7):e0179700. PubMed ID: 28678800
[TBL] [Abstract][Full Text] [Related]
27. Expression of LYN and PTEN genes in chronic myeloid leukemia and their importance in therapeutic strategy.
Ferri C; Bianchini M; Bengió R; Larripa I
Blood Cells Mol Dis; 2014; 52(2-3):121-5. PubMed ID: 24091144
[TBL] [Abstract][Full Text] [Related]
28. NKG2A Down-Regulation by Dasatinib Enhances Natural Killer Cytotoxicity and Accelerates Effective Treatment Responses in Patients With Chronic Myeloid Leukemia.
Chang MC; Cheng HI; Hsu K; Hsu YN; Kao CW; Chang YF; Lim KH; Chen CG
Front Immunol; 2018; 9():3152. PubMed ID: 30705677
[TBL] [Abstract][Full Text] [Related]
29. All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib.
Cassuto O; Dufies M; Jacquel A; Robert G; Ginet C; Dubois A; Hamouda A; Puissant A; Luciano F; Karsenti JM; Legros L; Cassuto JP; Lenain P; Auberger P
Oncotarget; 2012 Dec; 3(12):1557-65. PubMed ID: 23238683
[TBL] [Abstract][Full Text] [Related]
30. Current status and novel strategy of CML.
Morita K; Sasaki K
Int J Hematol; 2021 May; 113(5):624-631. PubMed ID: 33782818
[TBL] [Abstract][Full Text] [Related]
31. Perturbation of p38α MAPK as a Novel Strategy to Effectively Sensitize Chronic Myeloid Leukemia Cells to Therapeutic BCR-ABL Inhibitors.
Kuo YH; Wei SH; Jiang JH; Chang YS; Liu MY; Fu SL; Huang CF; Lin WJ
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830455
[TBL] [Abstract][Full Text] [Related]
32. Continuous Cytostatic Effects of BCR-ABL Tyrosine Kinase Inhibitors (TKIs) after Washout in Human Leukemic K562 Cells.
Aoyama T; Shibayama Y; Furukawa T; Sugawara M; Takekuma Y
Biol Pharm Bull; 2019 Nov; 42(11):1805-1813. PubMed ID: 31434819
[TBL] [Abstract][Full Text] [Related]
33. BCR-ABL mutational studies for predicting the response of patients with chronic myeloid leukaemia to second-generation tyrosine kinase inhibitors after imatinib failure.
Kwan TK; Ma ES; Chan YY; Wan TS; Liu HS; Sim JP; Yeung YM; Lie AK; Yip SF
Hong Kong Med J; 2009 Oct; 15(5):365-73. PubMed ID: 19801694
[TBL] [Abstract][Full Text] [Related]
34. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
35. [Hepatic adverse events associated with tyrosine kinase inhibitors in patients with chronic myeloid leukemia].
Dou XL; Wang SS; Fang JL; Yu L; Ren X; Huang XJ; Jiang Q
Zhonghua Nei Ke Za Zhi; 2018 Sep; 57(9):649-655. PubMed ID: 30180449
[No Abstract] [Full Text] [Related]
36. Dasatinib treatment can overcome imatinib and nilotinib resistance in CML patient carrying F359I mutation of BCR-ABL oncogene.
Barańska M; Lewandowski K; Gniot M; Iwoła M; Lewandowska M; Komarnicki M
J Appl Genet; 2008; 49(2):201-3. PubMed ID: 18436994
[TBL] [Abstract][Full Text] [Related]
37. The HDAC6 inhibitor 7b induces BCR-ABL ubiquitination and downregulation and synergizes with imatinib to trigger apoptosis in chronic myeloid leukemia.
Losson H; Gajulapalli SR; Lernoux M; Lee JY; Mazumder A; Gérard D; Seidel C; Hahn H; Christov C; Dicato M; Kirsch G; Han BW; Schnekenburger M; Diederich M
Pharmacol Res; 2020 Oct; 160():105058. PubMed ID: 32619722
[TBL] [Abstract][Full Text] [Related]
38. A retrospective study of the prescribing and outcomes of tyrosine kinase inhibitors in chronic myeloid leukaemia over a period of more than 10 years.
Lang AS; Mounier M; Roques M; Chretien ML; Boulin M
J Clin Pharm Ther; 2015 Aug; 40(4):391-7. PubMed ID: 25865674
[TBL] [Abstract][Full Text] [Related]
39. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase.
Kantarjian HM; Cortes J; La Rosée P; Hochhaus A
Cancer; 2010 Mar; 116(6):1419-30. PubMed ID: 20120030
[TBL] [Abstract][Full Text] [Related]
40. Ever-advancing chronic myeloid leukemia treatment.
Kimura S; Ando T; Kojima K
Int J Clin Oncol; 2014 Feb; 19(1):3-9. PubMed ID: 24258348
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]